🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 31 of 116

  1. AZD6738, Ceralasertib

    AstraZeneca AB

    Advanced Cancer Whose Tumours Contain Molecular Alterations

    phase 2 small molecule active

    1 trial

  2. AZD6738, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets, Ceralasertib, AZD6738

    AstraZeneca AB

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  3. AZD7789

    AstraZeneca AB

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  4. AZD8931

    United Therapeutics Europe Ltd

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  5. AZD8931

    AstraZeneca

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  6. AZD9291

    Hospital Authority, Hong Kong

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  7. AZD9291

    Samsung Bioepis NL B.V.

    Non-Small Cell Lung Cancer With EGFR T790M Mutation

    phase 2 small molecule active

    1 trial

  8. AZD9574, DS-8201a, TEMOZO-cell ®250 mg Hartkapseln, AZD9574, TEMOZO-cell® 140 mg Hartkapseln, TEMOZO-cell® 100 mg Hartkapseln, TEMOZO-cell® 20 mg Hartkapseln, AZD9574, TEMOZO-cell® 180 mg Hartkapseln, TEMOZO-cell® 5 mg Hartkapseln, AZD9574, Datopotamab deruxtecan

    AstraZeneca AB

    Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma

    phase 2 small molecule active

    1 trial

  9. AZD9750, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  10. AZD9793

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  11. AZITROMICINA ZENTIVA 500 mg compresse rivestite con film, Bassado 100 mg compresse, CEBION

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  12. Abemaciclib

    Teva Pharma GmbH

    Triple Negative Breast Neoplasms

    phase 2 small molecule active

    1 trial

  13. Abemaciclib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Metastases From Colorectal Cancer (mCRC)

    phase 2 small molecule active

    1 trial

  14. Abemaciclib, TEMOZOLOMIDE , Verzenios 50 mg film-coated tablets, IRINOTECAN

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  15. Abevmy 25 mg/mL concentrate for solution for infusion., CAPECITABINE VIATRIS 150 mg, comprimé pelliculé, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  16. Abexinostat

    Xynomic Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  17. Abiraterone Acetate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  18. Abiraterone Acetate

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  19. Abiraterone acetate

    United Therapeutics Europe Ltd

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  20. Abraxane

    Duke University

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  21. Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN, VALPROIC ACID, SIMVASTATIN, CAPECITABINE, VALPROIC ACID, GEMCITABINE

    Fondazione Telethon ETS

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  22. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  23. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  24. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  25. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  26. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  27. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  28. Acalabrutinib

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  29. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  30. Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Genmab A/S

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    phase 2 small molecule active

    1 trial

  31. Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, Tora-Dol 30 mg/ml soluzione iniettabile

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 2 small molecule active

    1 trial

  32. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Pediatric Brain Tumor

    phase 2 mab terminated

    1 trial

  33. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Metastatic Breast Cancer

    phase 2 mab terminated

    1 trial

  34. Ad-RTS-hIL-12 and Veledimex

    Alaunos Therapeutics

    Breast Cancer Nos Metastatic Recurrent

    phase 2 gene therapy terminated

    1 trial

  35. Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 other active

    1 trial

  36. Adebellizumab

    The First People's Hospital of Lianyungang

    Resectable Lung Non-Small Cell Carcinoma

    phase 2 small molecule active

    1 trial

  37. Adebrelimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  38. Adebrelimab (PD-L1 inhibitor)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer Metastatic

    phase 2 small molecule active

    1 trial

  39. Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  40. Adebrelimab+Albumin paclitaxel +Cisplatin

    The First People's Hospital of Lianyungang

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  41. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    The First People's Hospital of Lianyungang

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  42. Administration of experimental treatment association (sotorasib, panitumumab 5FU)

    NORTHWEST BIOTHERAPEUTICS INC

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  43. Aerobic exercise training

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 other completed

    1 trial

  44. Afatinib and Paclitaxel

    United Therapeutics Europe Ltd

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  45. Afatinib once daily (OD)

    Boehringer Ingelheim

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  46. Aflibercept

    Regeneron UK Limited

    Advanced Carcinoma

    phase 2 small molecule terminated

    1 trial

  47. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial

  48. Aglatimagene besadenovec

    Candel Therapeutics

    Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.